Marker Therapeutics (MRKR) Income from Continuing Operations (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Income from Continuing Operations of 4294075.0 for Q1 2026, up 10.45% year-over-year from 3887722.54 in Q1 2025, and down 88.19% quarter-over-quarter from 2281734.0 in Q4 2025.
Marker Therapeutics (MRKR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Income from Continuing Operations for 17 consecutive years, with 4294075.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 10.45% year-over-year to 4294075.0; the TTM figure through Mar 2026 stood at 12718479.0 (up 14.91% YoY), while the FY2025 annual figure was 9621233.0, up 10.34% from the prior year.
- Income from Continuing Operations eased to 4294075.0 in Q1 2026 per MRKR's latest filing, from 2281734.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1998662.0 in Q3 2025 and bottomed at 19880751.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 6196982.06 across 5 years, with a median of 4144008.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 77.09% — and 2025, when it slumped 54.05%.
- Marker Therapeutics' Income from Continuing Operations stood at 3135259.0 in 2022, then fell by 29.29% to 4053686.0 in 2023, then retreated by 2.76% to 4165438.0 in 2024, then jumped by 45.22% to 2281734.0 in 2025, then tumbled by 88.19% to 4294075.0 in 2026.
- Business Quant data shows MRKR's Income from Continuing Operations at 4294075.0 in Q1 2026, 2281734.0 in Q4 2025, and 1998662.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.29 Mn |
| Dec 31, 2025 | -2.28 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -4.14 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Sep 30, 2024 | -2.60 Mn |
| Jun 30, 2024 | -3.39 Mn |
| Mar 31, 2024 | -3.11 Mn |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -4.55 Mn |
| Mar 31, 2023 | -13.45 Mn |
| Dec 31, 2022 | -3.14 Mn |
| Sep 30, 2022 | -15.39 Mn |
| Jun 30, 2022 | -19.88 Mn |
| Mar 31, 2022 | -10.11 Mn |
| Dec 31, 2021 | -11.40 Mn |
| Sep 30, 2021 | -12.42 Mn |
| Jun 30, 2021 | -26.80 Mn |